Alteogen and Altos Biologics Decide on 29.5 Billion KRW Capital Increase
[Asia Economy Reporter Kim Daehyun] Alteogen announced on the 15th that its subsidiary Altos Biologics has decided to raise 29.5 billion KRW through a third-party allotment paid-in capital increase to secure operating funds.
Hot Picks Today
"Only 3 Passengers on a 180-Seat Flight"... The Shocking State of the 'Honeymoon Hotspot'
- "Work That Took a Month Now Done in Just 8 Hours"…Samsung and LG Turn to AI to Counter China's Pursuit
- "She Looks Different?" Online Searches Surge 1200%... The 'Filler in a Bottle' Captivating Women Chasing Youth
- "Neighbors Like This Still Exist"... A Warm Handwritten Letter from Downstairs Eases Concerns About Noise Between Floors
- "Part-Time Experience Now Reflected in Starting Salary, Monthly Pay Reaches 4.2 Million Won... 85.6% of Japanese University Students Secure Jobs Before Graduation"
The shares to be issued through this paid-in capital increase are 184,375 preferred shares, with a par value of 500 KRW per share.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
